• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Depakote ER (divalproex sodium)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Depakote ER (divalproex sodium)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Depakote ER is an extended-release product used to prevent or reduce the occurrence of migraines. It is indicated for the prevention of migraine headaches in adults; however, there is no evidence that it is useful in the acute treatment of migraine headaches. Depakote ER is provided in tablet form.

    About 23 million Americans suffer from migraine headaches, and approximately 75% of migraine sufferers are women. Migraines may also include nausea and/or vomiting, as well as sensitivity to light and sound.

    Clinical Results

    The results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial demonstrated the effectiveness of Depakote ER in the prevention of migraine headaches. Patients who experienced two migraine headaches in a four-week baseline period were randomized in a 1:1 ratio to Depakote ER or placebo and treated for 12 weeks. Patients began treatment on 500 mg once daily for one week, and were then increased to 1000 mg once daily with an option to decrease the dose back to 500 mg during the second week if intolerance occurred. 98 of 114 Depakote ER-treated patients (86%) and 100 of 110 placebo-treated patients (91%) treated at least two weeks maintained the 1000 mg once daily dose for the duration of their treatment. Treatment outcome was based on the reduction of the four-week migraine headache rate in the treatment period compared to the baseline period.

    Two hundred and two patients (101 in each treatment group) completed the treatment period. The mean reduction in the four-week migraine headache rate was 1.2 from a baseline mean of 4.4 in the Depakote ER group, versus 0.6 from a baseline mean of 4.2 in the placebo group. The treatment difference was statistically significant. (from FDA Label)

    Side Effects

    Adverse effects reported with Depakote ER use include (but are not limited to) the following:

    • Nausea
    • Diarrhea
    • Vomiting
    • Abdominal pain
    • Dizziness
    • Tremor
    • Weight gain
    • Back pain

    Depakote ER generally should not be administered to patients with hepatic (liver) disease or significant hepatic dysfunction.

    Before using Depakote ER, a woman who can become pregnant should consider the fact that Depakote ER has been associated with birth defects, in particular, with spina bifida and other defects related to failure of the spinal canal to close normally.

    Mechanism of Action

    Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically, it is designated as sodium hydrogen bis(2-propylpentanoate).

    Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. (from FDA Label).

    Additional Information

    For additional information on Depakote ER, please visit the web site of Abbott Laboratories.

    Approval Date: 2000-08-01
    Company Name: Abbott Laboratories
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing